gptkbp:instanceOf
|
gptkb:drug
selective progesterone receptor modulator
|
gptkbp:approvalYear
|
2009
2010
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:European_Medicines_Agency
|
gptkbp:ATCCode
|
G03AD02
|
gptkbp:brand
|
gptkb:Ella
gptkb:Esmya
|
gptkbp:CASNumber
|
126784-99-4
|
gptkbp:contraindication
|
pregnancy
severe liver disease
|
gptkbp:developedBy
|
HRA Pharma
|
gptkbp:discoveredBy
|
HRA Pharma
|
gptkbp:drugClass
|
oral contraceptive
hormonal medication
antiprogestogen
|
gptkbp:eliminationHalfLife
|
32 hours
|
gptkbp:excretion
|
urine
feces
|
gptkbp:hasMolecularFormula
|
C30H37NO4
|
https://www.w3.org/2000/01/rdf-schema#label
|
ulipristal acetate
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:mechanismOfAction
|
progesterone receptor antagonist
|
gptkbp:metabolism
|
liver
|
gptkbp:pregnancyCategory
|
D
X
contraindicated
|
gptkbp:pregnancyCategoryEU
|
contraindicated
|
gptkbp:prescriptionStatus
|
prescription only
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
135565087
24609941
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
nausea
abdominal pain
fatigue
headache
dysmenorrhea
|
gptkbp:synonym
|
CDB-2914
VA2914
17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione
|
gptkbp:UNII
|
Y5L0U73M7A
|
gptkbp:usedFor
|
oral contraceptive
treatment of uterine fibroids
|
gptkbp:bfsParent
|
gptkb:EC_stack
|
gptkbp:bfsLayer
|
7
|